Tradestie Institutional Equity Comparison Engine

VRAX vs AKAN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

AKAN Overall Edge

AKAN Captures Institutional Edge (2โ€“1 Pillars ยท 4โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Akanda Corp. Common Shares (AKAN) driven by superior Growth & Margin, Momentum & Technical while VRAX counters with relative strength in Options & Structure. Fundamentally, VRAX trades at N/M Forward P/E with -51515.2% operating margin (+684.9% YoY revenue) versus AKAN at N/M Forward P/E and -1254.5% operating margin (+21.9% YoY). In options structure, VRAX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against AKAN sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
VRAX N/M vs AKAN N/M Fwd P/E
Growth & Margin Winner AKAN
Op Margin -51515.2% vs -1254.5% ยท YoY +684.9% vs +21.9%
Momentum & Technical Winner AKAN
1Y -24.6% vs +358.3% ยท 52W Pos 2% vs 5%
Options & Structure Winner VRAX
UNCLASSIFIED (N/A IV) vs BREAKDOWN (N/A IV)
VRAX NASDAQ
Virax Biolabs Group Limited Ordinary Shares
In Vitro & In Vivo Diagnostic Substances
$0.33
-12.89% 1D
Market Cap $470,745
1M Return -73.13%
1Y Return -24.62%
Forward P/E N/M
Unified AI Score
46.5 / 100 HOLD
Tech 45.0 Fund 50.0 Flow 50.0 Mom 55.0
AKAN NASDAQ
Akanda Corp. Common Shares
Medicinal Chemicals & Botanical Products
$4.23
+23.32% 1D
Market Cap $12.2M
1M Return +267.83%
1Y Return +358.29%
Forward P/E N/M
Unified AI Score
39.8 / 100 SELL
Tech 15.0 Fund 36.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: VRAX -24.62% AKAN +358.29% Spread: +382.91 pp (AKAN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
VRAX TTM Op. Margin: -51515.2% AKAN TTM Op. Margin: -1254.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VRAX vs AKAN. Trailing 12-month operating profitability (VRAX -51515.2% vs AKAN -1254.5%) and valuation multiples (VRAX N/M vs AKAN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: VRAX (3) vs AKAN (4)
Institutional Metric VRAX AKAN Criterion Row Winner
Market Capitalization Scale $470,745 $12.2M Larger Scale AKAN
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +684.9% +21.9% Higher Growth VRAX
Operating Margin (TTM) Profitability -51515.2% -1254.5% Higher Margin AKAN
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -78.6% -60.9% Higher ROE AKAN
52-Week Range Position Momentum 2% ($0โ€“$13) 5% ($0โ€“$79) Stronger Trend AKAN
Beta / 30D Volatility Risk Regime -8.20ฮฒ ยท 162% Vol 4.82ฮฒ ยท 524% Vol Lower Realized Risk VRAX
Unified Institutional Score Composite Signal 46.5 / 100 (HOLD) 39.8 / 100 (SELL) Higher Composite VRAX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full VRAX vs AKAN Buy Guide
VRAX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live VRAX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
AKAN BREAKDOWN
140d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live AKAN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither VRAX nor AKAN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.